Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture

Next Previous
Trial Profile

Randomized, Doubel-blinded, Parallel, Active-controlled Phase III Study, to Evaluate the Efficacy and Safety of CMAB807 Treatment Compared With Prolia in Chinese Postmenopausal Women With Osteoporosis at High Risk of Fracture

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Denosumab (Primary) ; Calcium; Vitamin D
  • Indications Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Sponsors Shanghai Biomabs Pharmaceuticals

Most Recent Events

  • 20 Feb 2025 Status changed from recruiting to completed.
  • 25 Mar 2024 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.
  • 25 Mar 2024 Planned primary completion date changed from 1 Oct 2023 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top